

Related Companies | [] | ||||||||
Related Funds | [] | ||||||||
English | |||||||||
oda_MaterialEventDisclosureGeneralAbstract| |
| ||||||||
oda_UpdateAnnouncementFlag| |
| Hayır (No) | |||||||
oda_CorrectionAnnouncementFlag| |
| Hayır (No) | |||||||
oda_DateOfThePreviousNotificationAboutTheSameSubject| |
| - | |||||||
oda_DelayedAnnouncementFlag| |
| Hayır (No) | |||||||
oda_AnnouncementContentSection| |
| ||||||||
oda_ExplanationSection| |
| ||||||||
oda_ExplanationTextBlock| | Med Service Plus Company, authorized by the Representative Office of our company, GEN İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) in Kazakhstan, participated in the pharmaceutical procurement tender organized by SK Pharmacy, the official agency of the Ministry of Health of the Republic of Kazakhstan. As a result of the aforementioned tender, 'Intrafen', manufactured at GEN's Production Facility in Ankara, has won the Ibuprofen tender in Kazakhstan. The agreement, with the first drug delivery scheduled for November 2026, will cover the year 2027 and is expected to contribute a total of USD 1,188,681 to GEN's sales.
In case of any discrepancy between the Turkish and English texts, the Turkish text shall prevail. | ||||||||
We proclaim that our above disclosure is in conformity with the principles set down in “Material Events Communiqué” of Capital Markets Board, and it fully reflects all information coming to our knowledge on the subject matter thereof, and it is in conformity with our books, records and documents, and all reasonable efforts have been shown by our Company in order to obtain all information fully and accurately about the subject matter thereof, and we’re personally liable for the disclosures.